Antibacterial Drugs Market to reach USD 40 Billion by 2020

According to a market research report published by iHealthcareAnalyst, Inc., Antibacterial Drugs Market – Global Antibacterial Drug Classes, Clinical Pipeline Analysis and Forecast 2013-2020, the global antibacterial drugs market is estimated to reach USD 40 Billion by 2020 due to high incidence of infectious diseases.

Browse the Antibacterial Drugs Market – Global Antibacterial Drug Classes, Clinical Pipeline Analysis and Forecast 2013-2020 at http://www.ihealthcareanalyst.com/report/antibacterial-drugs-market/

Antibacterial drugs are derived from bacteria or molds or are synthesized de novo and can be classified in several ways - bacteriostatic or bacteriocidal, by chemical structure, according to their mode of action, or according to their spectrum of activity. Antibiotics have many mechanisms of action, including inhibiting cell wall synthesis, increasing cell membrane permeability, and interfering with protein synthesis, nucleic acid metabolism, and other metabolic processes (e.g. folic acid synthesis). The antibacterial drugs market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes (aminoglycosides; β-lactams including penicillins, carbapenems, cephalosporin; macrolides; phenicols; quinolones/fluoroquinolone; sulfonamides; and tetracyclines) and clinical pipeline analysis of phase 1,2 and 3 drugs, and forecasts growth trends (CAGR% - 2015 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.

The global antibacterial drugs market is segmented as:

1. Drug Class
1.1. Aminoglycosides
1.2. β-Lactams
1.2.1. Penicillin
1.2.2. Carbapenem
1.2.3. Cephalosporin
1.3. Macrolides
1.4. Phenicols
1.5. Quinolones/Fluoroquinolones
1.6. Sulfonamides
1.7. Tetracyclines
1.8. Other Antibacterials

2. Pipeline Analysis
2.1. Actoxumab/bezlotoxumab (MK-3415A)
2.2. Arikace
2.3. Cadazolid
2.4. Carbavance (meropenem/RPX7009)
2.5. Ciprofloxacin/Fluocinolone
2.6. Delafloxacin
2.7. Delamanid
2.8. Eravacycline
2.9. Omadacycline (PTK-0796)
2.10. Ozenoxacin
2.11. Plazomycin
2.12. RHB-105
2.13. Solithromycin
2.14. SPL7013
2.15. Surotomycin (MK-4261)
2.16. SYM-1219
2.17. Zempia (E-101)

3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World

4. Company Profiles
4.1. Allergan plc.
4.2. AstraZeneca plc.
4.3. Bayer
4.4. Bristol-Myers Squibb Company
4.5. Eli Lilly and
4.6. GlaxoSmithKline plc.
4.7. Johnson & Johnson
4.8. Merck & Co., Inc.
4.9. Novartis AG
4.10. Pfizer, Inc.
4.11. Sanofi

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Phone: (314) 736-9294.
Email: sales@ihealthcareanalyst.com
http://www.ihealthcareanalyst.com

This release was published on openPR.